<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery</h2>
    <div class="badge">2025-09-15T11:27:45+00:00</div>
    <ul>
      <li>Result: Fair Value of $2.55 (ABOUT RIGHT) See our latest analysis for Absci.</li>
<li>Shares have dropped around 34% over the past year, even as the company has raised fresh funding and added new scientific expertise in its core areas.</li>
<li>Price-to-Book of 2.2x: Is it justified?</li>
<li>This partnership is landing after a year of mixed fortunes for Absci’s stock.</li>
<li>Absci is currently trading at a price-to-book (P/B) ratio of 2.2x, which is in line with the average for the US Biotechs industry but below its immediate peer group.</li>
<li>This offers a snapshot of how much investors are willing to pay for each dollar of net assets.</li>
<li>The price-to-book ratio compares the market price of a company’s shares to its book value per share.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Absci%20%28ABSI%29%20Valuation%20in%20Focus%20Following%20Partnership%20With%20Oracle%20Cloud%20and%20AMD%20for%20AI%20Drug%20Discovery%0A%E2%80%A2%20Result%3A%20Fair%20Value%20of%20%242.55%20%28ABOUT%20RIGHT%29%20See%20our%20latest%20analysis%20for%20Absci.%0A%E2%80%A2%20Shares%20have%20dropped%20around%2034%25%20over%20the%20past%20year%2C%20even%20as%20the%20company%20has%20raised%20fresh%20funding%20and%20added%20new%20scientific%20expertise%20in%20its%20core%20areas.%0A%E2%80%A2%20Price-to-Book%20of%202.2x%3A%20Is%20it%20justified%3F%0A%E2%80%A2%20This%20partnership%20is%20landing%20after%20a%20year%20of%20mixed%20fortunes%20for%20Absci%E2%80%99s%20stock.%0A%E2%80%A2%20Absci%20is%20currently%20trading%20at%20a%20price-to-book%20%28P%2FB%29%20ratio%20of%202.2x%2C%20which%20is%20in%20line%20with%20the%20average%20for%20the%20US%20Biotechs%20industry%20but%20below%20its%20immediate%20peer%20group.%0A%E2%80%A2%20This%20offers%20a%20snapshot%20of%20how%20much%20investors%20are%20willing%20to%20pay%20for%20each%20dollar%20of%20net%20assets.%0A%E2%80%A2%20The%20price-to-book%20ratio%20compares%20the%20market%20price%20of%20a%20company%E2%80%99s%20shares%20to%20its%20book%20value%20per%20share.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fabsci-absi-valuation-in-focus-following-partnership-with-oracle-cloud-and-amd-fo%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/absci-absi-valuation-focus-following-112745982.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>